Added to YB: 2025-11-14
Pitch date: 2025-11-12
NKTR [neutral]
Nektar Therapeutics
+32.13%
current return
Author Info
Clinical Catalysts breaks down the science and strategy behind pharma market movers. Sign up for the newsletter.
Company Info
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally.
Market Cap
$2.1B
Pitch Price
$55.90
Price Target
N/A
Dividend
N/A
EV/EBITDA
-15.58
P/E
-9.34
EV/Sales
31.35
Sector
Pharmaceuticals
Category
growth
This Small-Cap Biotech Just Released Its Late-Breaking Data (And It Didn’t Disappoint) - Nektar Therapeutics
NKTR (update): Rezpeg Phase 2b REZOLVE-AD trial showed 61% EASI improvement vs 31% placebo in atopic dermatitis. New data reveals 75% of high-dose patients with comorbid asthma achieved clinically significant improvement vs 13% placebo. Crossover patients hit 75% EASI reduction by week 24, deepening with time.
Read full article (3 min)